China CAS:51333-22-3 Manufacturer

Our primary intention should be to offer our clientele a serious and responsible enterprise relationship, delivering personalized attention to all of them for CAS:51333-22-3, We're seeking forward to forming successful business enterprise romantic relationship with new shoppers in the around upcoming!
CAS:51333-22-3, With its rich manufacturing experience, high-quality products, and perfect after-sale service, the company has gained good reputation and has become one of the famous enterprise specialized in manufacturing series.We sincerely hope to establish business relation with you and pursue mutual benefit.

Hot Products

  • Methylprednisolone Hemisuccinate

    Methylprednisolone Hemisuccinate

    For Methylprednisolone Hemisuccinate, we have EP, USP and CP specification. DMF and WC available.

    CAS:2921-57-5

  • Ganciclovir

    Ganciclovir

    Ganciclovir has CP ,EP, USP specification. DMF and GMP approved.

    CAS:82410-32-0

  • Testosterone

    Testosterone

    Testosterone has CP,EP and USP specifications. CEP, DMF, WC, FDA available..

    CAS:58-22-0

  • Valganciclovir Hydrochloride

    Valganciclovir Hydrochloride

    Valganciclovir Hydrochloride has USP specification. DMF approved.

    CAS:175865-59-5

  • 17a-Hydroxyprogesterone

    17a-Hydroxyprogesterone

    17a-Hydroxyprogesterone is an endogenous progesteroid hormone similar to progesterone.

    CAS:68-96-2

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept